Professional
Added to YB: 2024-10-22
Pitch date: 2024-09-30
PCVX [bullish]
Vaxcyte, Inc.
-61.15%
current return
Author Info
No bio for this author
Company Info
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Market Cap
$6.4B
Pitch Price
$114.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.04
P/E
-10.06
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Baron Health Care Fund New Position: Vaxcyte, Inc.
PCVX: Next-gen pneumococcal vaccine platform shows superior efficacy vs incumbents. VAX31 covers 95% US & 98% EU strains, matching/beating Pfizer's PCV20 + 11 new serotypes. $10B+ market potential by 2030. Phase 3 adult & Phase 1/2 pediatric trials upcoming. Durable business with significant market share potential.
Read full article (1 min)